| 5.71 -0.08 (-1.38%) | 06-10 11:16 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.46 |
1-year : | 8.71 |
| Resists | First : | 6.38 |
Second : | 7.46 |
| Pivot price | 5.84 |
|||
| Supports | First : | 5.9 |
Second : | 5.59 |
| MAs | MA(5) : | 5.77 |
MA(20) : | 5.9  |
| MA(100) : | 6.1 |
MA(250) : | 6.59 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 39.3 |
D(3) : | 21.7 |
| RSI | RSI(14): 55.9 |
|||
| 52-week | High : | 9.63 | Low : | 5.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CSBR ] has closed below upper band by 14.6%. Bollinger Bands are 31.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.01 - 6.04 | 6.04 - 6.07 |
| Low: | 5.59 - 5.63 | 5.63 - 5.67 |
| Close: | 5.73 - 5.79 | 5.79 - 5.85 |
Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.
Wed, 03 Jun 2026
CSBR Technical Analysis & Stock Price Forecast - Intellectia AI
Thu, 28 May 2026
Champions Oncology Inc. (CSBR) Q1 2026 Earnings: Earnings Miss Estimates as EPS Falls to -$0.02 - Special Dividend Alert - The Legal Advocate
Mon, 30 Mar 2026
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy - ACCESS Newswire
Mon, 30 Mar 2026
Champions Oncology taps data-focused cancer doctor for board seat - Stock Titan
Thu, 12 Mar 2026
CHAMPIONS ONCOLOGY ($CSBR) Releases Q3 2026 Earnings - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 26.6 (%) |
| Held by Institutions | 47.7 (%) |
| Shares Short | 85 (K) |
| Shares Short P.Month | 82 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.31 |
| Profit Margin | -4.1 % |
| Operating Margin | -1.2 % |
| Return on Assets (ttm) | -4.7 % |
| Return on Equity (ttm) | -47.6 % |
| Qtrly Rev. Growth | -2.8 % |
| Gross Profit (p.s.) | 1.91 |
| Sales Per Share | 4.17 |
| EBITDA (p.s.) | -0.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 4 (M) |
| Levered Free Cash Flow | 5 (M) |
| PE Ratio | -33.53 |
| PEG Ratio | 0 |
| Price to Book value | 19.46 |
| Price to Sales | 1.44 |
| Price to Cash Flow | 19.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|